Clinical Pharmacology · Nov 14, 2026
The Growing Role of Glucagon-Like Peptide-1 Receptor Agonists in Neuropsychiatry
By Buyuksandalyaci Tunc E, Park M, Kansara R et al.
The co-occurrence of metabolic and psychiatric disorders poses a major challenge in medicine, and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as candidates for neuropsychiatric repurposing given the wide distribution of glucagon-like peptide-1 (GLP-1) receptors in brain regions governing mood, cognition, and reward. This narrative review summarizes central and peripheral mechanisms linking GLP-1 signaling to neuropsychiatric outcomes, critically appraises clinical evidence across psychiatric and neurodegenerative domains, and proposes a framework for integrating GLP-1RAs into neuropsychiatric care. A targeted search of PubMed/MEDLINE and ClinicalTrials.gov (January 2015-August 2026) prioritized randomized controlled trials, meta-analyses, and prospective cohorts reporting neuropsychiatric outcomes. Four converging mechanisms- neuroinflammation, metabolic-vascular neuroprotection, synaptic plasticity, and mesolimbic reward modulation- underpin this rationale. The strongest and most clinically actionable evidence supports GLP-1RA use for antipsychotic-induced metabolic dysfunction, with trials in clozapine/olanzapine-treated patients showing substantial weight loss and glycemic normalization without psychiatric worsening or altered clozapine levels. By contrast, in Alzheimer's disease, despite consistent observational signals of 33-53% dementia risk reduction, Phase 3 EVOKE/EVOKE+ trials found no benefit of oral semaglutide in early symptomatic disease despite biomarker engagement, favoring a prevention- rather than treatment-focused framework. Evidence in Parkinson's disease and major depressive disorder remains more limited: motor benefit in Parkinson's disease appears restricted to short-acting agents, with the largest phase 3 trial negative, while broad antidepressant efficacy is unsupported, although semaglutide improved effort-based decision-making in anhedonic, metabolically burdened patients. Additional signals exist for alcohol use disorder, binge eating disorder, and obstructive sleep apnea. Psychiatric safety appears reassuring across meta-analyses of over 133,000 participants, though exclusion of psychiatric populations from pivotal trials limits generalizability. Current evidence supports selective, investigational use of GLP-1RAs in neuropsychiatric care- most robustly for antipsychotic-induced metabolic dysfunction- rather than generalized repurposing, pending adequately powered trials with neuropsychiatric endpoints, structured monitoring, and equitable access strategies.
doi.org/10.2147/cpaa.s580850Open accessPubMed 43054852Interventions